Tourmaline Bio Inc
TRML
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.23B
Close$
$1.19
97.5% downside
Current Fair Value
97.5% downsideOvervalued by 97.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.23 Billion |
|---|---|
| Enterprise Value | $1.20 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.89 |
| Beta | 1.58 |
| Outstanding Shares | 25,755,000 |
Return
| Return on Equity | -34.13% |
|---|---|
| Return on Assets | -32.85% |
| Return on Invested Capital | -39.54% |
Valuation & Multiples
| P/E Ratio | -18.09 |
|---|---|
| PEG | -56.45 |
| Price to Sales | - |
| Price to Book Ratio | 4.8 |
| Enterprise Value to Revenue | 30034.33 |
| Enterprise Value to EBIT | -11.72 |
| Enterprise Value to Net Income | -14 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
November 6, 2025
EPS Estimate
$-0.96
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 2.5940▲ 259.40% |
|---|---|
| Total Calls | 29,800▲ Infinity% |
| Total Puts | 77,300▲ Infinity% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 84.03%▼ 9.41% |
|---|---|
| Total Invested | $1.04B▲ 169.01% |
| Investors Holding | 141▲ 34.00% |
ESG Score
No data
About Tourmaline Bio Inc
125 employeestalaris therapeutics is a late-clinical stage biotechnology company based in boston, ma and louisville, ky. talaris is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for o...